Feb 07,2022

Accuracy of Continuous Glucose Monitors for Inpatient Diabetes Management

In hospitalized patients, continuous glucose monitoring (CGM) may improve glycemic control, prevent hypoglycemic events, and reduce staff workload compared with point-of-care (POC) capillary glucose monitoring. This study is to evaluate CGM accuracy and safety of use in the inpatient setting, two versions of CGM sensors were placed on 43 and 34 adult patients with diabetes admitted to non-intensive care unit (ICU) medical wards, respectively.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 07,2022

Key Considerations for Understanding Usability of Digital Health Initiatives for Adults With Type 2 Diabetes: A Systematic Qualitative Literature Review

This systematic qualitative literature review aimed to understand usability of digital health initiatives for adults with type 2 diabetes.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 08,2022

DTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growth

DTx leader Sidekick announces key C-level hires in move to accelerate U.S. market growth. UnitedHealth Group and Anthem veteran Pamela Stahl joins as Chief Commercial Officer (CCO) and President, North America to lead Sidekick’s global commercial strategy, driving revenue growth with international pharmaceutical majors and U.S.-based payers. Mitchell Mudra joins Sidekick from UnitedHealth Group as Chief Operating Officer (COO), scaling the company’s operations and user volumes in close collaboration with its pharmaceutical and payer partners in the U.S. and beyond.

View Analyst & Ambassador Comments
Go to original news
Feb 09,2022

The Effectiveness of Telemedicine Solutions in Type 1 Diabetes Management: A Systematic Review and Meta-analysis

This study aims to conduct a systematic review of the effectiveness of telemedicine solutions versus any comparator on diabetes-related outcomes among people with T1D.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 09,2022

One Drop’s Multi-Condition Program Achieves Third-Party Validation for Simultaneous Improvement of Blood Glucose and Blood Pressure Outcomes

One Drop, a leader in precision health solutions for people living with chronic conditions worldwide, today announced its multi-condition program has received validation for clinical outcomes from Validation Institute. The 2022 validation report verifies claims for One Drop's principal multi-condition studies demonstrating clinical outcomes for prediabetes, diabetes, and hypertension.

View Analyst & Ambassador Comments
Go to original news
Feb 09,2022

EHE Health and Welldoc Announce Strategic Partnership to Launch Thrive Now

EHE Health, a national healthcare provider network and top innovator in preventive healthcare, and Welldoc, a digital health leader revolutionizing chronic care, announced a partnership to launch Thrive Now by EHE Health, a digital health platform designed to help manage members’ overall total health.

COLLABORATION PARTNERSHIP

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 09,2022

DarioHealth Publishes Clinical Outcomes Demonstrating the Impact of Using a Single Digital Therapeutics Platform for Multiple Conditions

New peer-reviewed study sheds light on the effectiveness of an integrated approach for Dario users with both diabetes and high blood pressure.

CLINICAL STUDY

#dtx

View Analyst & Ambassador Comments
Go to original news
Feb 09,2022

Terumo Revises its Full-Year Financial Guidance for FY2021

Terumo Corporation (TSE: 4543) today announced that it revised the full-year financial guidance for the year ending March 2022 (FY2021) from its last announcement on August 4, 2021.

View Analyst & Ambassador Comments
Go to original news
Feb 11,2022

Tandem Diabetes Care Announces Upcoming Virtual Conference Presentations

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) announced that management will present a company update at the following virtual investor conferences: Citi’s 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 11:00am Eastern Time (8:00am Pacific Time), and Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 2:50pm Eastern Time (11:50am Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 14,2022

ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS

Ascensia Diabetes Care, a global diabetes care company, announces that its partner Senseonics Holdings, Inc. (NYSE American: SENS) has received approval from the U.S. Food and Drug Administration (FDA) for the next-generation Eversense ® E3 Continuous Glucose Monitoring (CGM) System. Ascensia plans to make the Eversense E3 sensor, which can be used for up to 6 months, available to patients in the U.S. during the second quarter of 2022.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES